Clinical trial
Favipiravir Combined With Tocilizumab in the Treatment of Corona Virus Disease 2019-A Multicenter, Randomized and Controlled Clinical Trial Study
NCT04310228 is registered in ClinicalTrials.gov with Peking University First Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Favipiravir Combined With Tocilizumab in the Treatment of Corona Virus Disease 2019-A Multicenter, Randomized and Controlled Clinical Trial Study
- Lead sponsor
- Peking University First Hospital
- Phase
- Not applicable
- Overall status
- Unknown status
- Start date
- March 8, 2020
- Completion date
- May 31, 2020
- Enrollment
- 150 (estimated)
- Sites
- 6
Conditions
As the registry lists them; a condition with its own page is linked.